COMPANY

In the News

TOBA III Roundtable Discussion: Thomas Zeller, MD, Marianne Brodmann, MD (PI), and Michael Lichtenberg, MD

Tack Endovascular System: FDA Approved

TOBA II 12-month pivotal trial data, presented by Dr. William A. Gray 

Post-PTA Dissection: Clinical Impact, Identification, and Repair

Intact Vascular Receives Conditional FDA Approval for TOBA II Study of Tack System

Intact Vascular’s Tack Endovascular System Supported by 12-Month TOBA Data

TOBA II shows repairing dissections after angioplasty “clearly augments” outcomes for PAD patients. 

Using the Tack Endovascular System to treat vessel dissection 

Intact Vascular Announces Conditional FDA Approval for TOBA II Study and Enrolment of First Patients

Positive 12-Month Results of TOBA Clinical Trial

TOBA II shows repairing dissections after angioplasty “clearly augments” outcomes for PAD patients. 

Start-Ups Across Health Care: Intact Vascular Inc. Optimizing balloon angioplasty for peripheral arterial disease

PURPOSE–BUILT. PRECISION REPAIR. PRESERVES OPTIONS.